Abstract
Acute respiratory distress syndrome (ARDS) is a life-threatening situation in patients on the ICU. Most patients have to be ventilated mechanically to provide adequate oxygenation. Reduction of tidal volumes as low as 6 ml/kg adjusted bodyweight has been convincingly shown to reduce ARDS and mortality in the ARDSnet trial [1] and is now recommended in treating such patients. In the ARDSnet trial, body weight has been calculated by a formula implementing the body height [1]. We suggest that in most patients on ICUs the correct height is not known or is at best estimated, but very seldom correctly measured. We searched for both an easily obtainable and reproducible body mark to correctly predict body height. Anthropological and forensic data have shown a close correlation between the ulna length and body size. We prospectively measured body height and right and left ulna length in ventilated ICU patients.
Highlights
There is considerable uncertainty about the reproducibility of the various instruments used to measure dyspnea, their ability to reflect changes in symptoms, whether they accurately reflect the patient’s experience and if its evolution is similar between acute heart failure syndrome patients and nonacute heart failure syndrome patients
Results of this study show that early tracheostomy, if perioperative complications
We looked at the use of postwith tracheostomies performed in the critical care unit of a tertiary procedure chest radiography (CXR)
Summary
There is considerable uncertainty about the reproducibility of the various instruments used to measure dyspnea, their ability to reflect changes in symptoms, whether they accurately reflect the patient’s experience and if its evolution is similar between acute heart failure syndrome patients and nonacute heart failure syndrome patients. Conclusions Our data demonstrate that critically ill patients may be exposed to a higher FiO2 than that required to maintain adequate oxygenation These results highlight an area of ICU care that has received little study, with no published clinical trials examining the effect of FiO2 on outcome. Results Age, sex, the underlying disease and tumour stage (TNM classification), type of previous anticancer treatment, performance status, severity scores (APACHE II, Simplified Acute Physiology Score II, Sequential Organ Failure Assessment), ICU and hospital mortalities and hospital outcome at 3, 6 and 12 months were analysed. Clinical data of 277 post-transplantation patients admitted to the ICU were collected at admission and the SAPS 3 and APACHE II score calculated with respective estimated mortality rates.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
